论文部分内容阅读
目的:观察中药复方肌力康饮对实验性自身免疫性重症肌无力(EAMG)大鼠血清AchR-Ab、TGF-β1水平的影响,以探讨其治疗重症肌无力的可能机制。方法:60只Lewis大鼠随机分为6组,每组10只:空白组,模型组,阳性药物组,肌力康饮高、中、低剂量组。采用AchR主动免疫的方法免疫除空白组外的各组大鼠,制备EAMG大鼠模型。确立模型成功,各组给药治疗4周后,采用ELISA法检测血清AchR-Ab、TGF-β1水平。结果:肌力康饮各组、阳性药物组能明显改善EAMG大鼠肌无力症状,临床症状评分显著降低、血清AchR-Ab水平明显下降、TGF-β1水平明显升高,与模型组比较,有显著性差异(P<0.01);肌力康饮高剂量组与阳性药物组比较亦有明显差异(P<0.05);但肌力康饮各剂量组之间比较无显著性差异(P>0.05)。结论:肌力康饮下调了EAMG大鼠过高的AchR-Ab水平,并使TGF-β1升高,从而改善了EAMG大鼠的临床症状。
OBJECTIVE: To observe the effect of Qiliangkangyin on the serum levels of AchR-Ab and TGF-β1 in experimental autoimmune myasthenia gravis (EAMG) in rats to explore its possible mechanism of treating myasthenia gravis. Methods: Sixty Lewis rats were randomly divided into six groups (n = 10 each): blank group, model group, positive drug group, and qikelin high, medium and low dose groups. The AchR active immunization method was used to immunize rats in each group except the blank group to prepare the EAMG rat model. The model was established successfully. After four weeks of treatment, the serum levels of AchR-Ab and TGF-β1 were detected by ELISA. Results: Each group of KICG and the positive drug group can obviously improve the symptom of myasthenia in EAMG rats, the scores of clinical symptoms were significantly decreased, the level of serum AchR-Ab was obviously decreased and the level of TGF-β1 was obviously increased. Compared with the model group, (P <0.01). There was also a significant difference between the high dose group and the positive drug group (P <0.05), but there was no significant difference between each dose group of Qilikang (P> 0.05) ). Conclusion: Qilikang down-regulated the level of AchR-Ab in EAMG rats and increased TGF-β1, thus improving the clinical symptoms of EAMG rats.